Factors Influencing AVF Dysfunction in Patients with Maintenance Hemodialysis: A retrospective study

2.1 Research object

2.2. Research methods

3.1. Follow-up results and overall patency of fistula

Generally, 121 patients with ESRD were included in our center. Of the 121 patients, 23 were lost to follow-up, 10 received kidney transplant, and 11 died. 77 patients who met the inclusion criteria were included in the analysis. Among them, 53 (68.8%) were male whereas 24 (31.2%) were female. The participants ranged from 29-82 years old, with an average age of (56.5±11.3) years. Diabetic and non-diabetic nephropathy accounted for 47 (61.0%) and 30 (39.0%) of ESRD cases. All AVFs were matured, and the follow-up ranged from 5 to 39 month with a mean of (20.9 ± 10.1) month. Meanwhile, the follow-up period of patients in patency group and dysfunction group was (19.7±9.9) month and (22.8±10.2) months, respectively. Since the follow-up period was non normal distribution, Mann Whitney U test was performed, and there was no statistically significant difference between the patency and dysfunction groups (P = 0.191). During the observation period, 30 (39.0%) patients developed AVF dysfunction whereas 47 (61.0%) patients did not.

3.2. Comparison of baseline between patency and dysfunction group

The clinical and demographic characteristics of the entire study cohort are summarized in Table 1. A total of 21 study factors were included and compared between the patency and dysfunction group. P-values of five variables were less than 0.1, which were Gender, Phosphorus, Calcium Phosphorus product, TC and LDL. However, there was no significant difference for other factors. (Table 1).

Factors influencing development of AVF

Over the past 50 decades, there has been a growing consensus of “fistula first” principle in patients with MHD. The guidelines, published in 1997 (1) and revised in 2003 (2) and 2006 (3), together with the “fistula first” principle proposed in 2003 (4), suggests that AVF is the optimal choice. Although AVF is associated with thrombosis, blood steal syndrome and aneurysm, incidence of these complications are relatively low for AVF nowadays. Many factors, such as blood calcium, phosphorus and lipid (5), CRP (6), SCr; vascular diameter (7) and preoperative radial artery calcification (RAC) (8), can not only be caused by renal failure (9) but also affect the patency of AVFs. Although some studies have reported some of these risks, many have not been exhaustive.

Since the “fistula first” principle in 2003 (10), clinicians have increasingly preferred AVF for HMD. However, studies show that the AVF failure ranges between 15% and 22% (2,11). Currently, little emphasis has been putted on preoperative internal environment. Recent studies suggest that the internal environmental factors of AVFs are important (12). In this study, we found TC and phosphorus to be independent risk factors for AVF dysfunction.

4.1 Age

Most elderly patients present with other underlying diseases. As such, they may not harness optimal benefits from certain disease interventions, evidenced by short survival rate (13). In a separate but related study, it was found that the advantages of AVF over central venous catheter (CVC) gradual decreases with age. However, the disadvantages of AVF are gradually amplified. As such, CVC usage may be preferred in elderly patients. Meanwhile, the study shows that among the patients who have die of CKD, 35% of them were on AVF (14). Therefore, the huge loss is not worthy undisputedly embracing “fistula first”. Combined with findings of this study, age is not an independent risk factor for AVF dysfunction. Generally, age of patients does not affect the primary patency rate of AVF, but affect the long-term benefits. At the same time, from an economic point of view, AVF use for dialysis in elderly patients may be counterproductive. In a related study, K. hall et al. (15) established a Markov model from retrospective data to analyze the input-output ratio of patients with AVF, arteriovenous graft (AVG) and CVC. They found the input-output of AVF against AVG and CVC gradually declines with patients’ age. Thamer M et al. (16) also showed that in the whole age population, the average annual cost of maintaining AVF patency for 2.5 years is $7871 whereas that of patients with primary dysfunction is $13282 per year. So, the benefits of AVF in elderly patients are sub-optimal.

4.2 Serum total cholesterol (TC)

Blood lipid plays an important role in the patency of arteriovenous fistula. This research shows that TC is an independent risk factor for AVF dysfunction (17). Generally, high-density lipoprotein (HDL) is a protective factor for AVF dysfunction. Wang et al. (18) demonstrated that higher TT increases the risk of AVF dysfunction. In this research, TC was an independent risk factor for AVF, but TT was not. This discrepancy may however be attributed to our small sample size. Mechanistically, hyperlipidemia activates vascular endothelial growth factor A/matrix metalloproteinase-9 signaling pathway, which causes intimal hyperplasia and atherosclerosis (16).

4.3 Blood phosphorus

Many studies have implicated blood phosphorus for AVF dysfunction. Moon and Lee (19) showed that hyperphosphatemia (blood phosphorus > 5.5mg/ml) has a strong positive correlation with AVF dysfunction within 1 year of its induction. In a related study, Zhou Min and Lu Fangping (20) found that patients with hyperphosphatemia were more likely to develop AVF dysfunction than their normal counterparts. They found hyperphosphatemia to be an independent risk factor for AVF dysfunction, consistent with our findings. Continuous exploration of vascular access dysfunction has drawn interest in vascular calcification. Blood phosphorus has been implicated for vascular calcification. Here, prolonged hyperphosphatemia transforms vascular smooth muscle cells (VSMC) into osteoblast like cells (21). This induces calcium and phosphorus deposition on the inner wall of blood vessels, thus causing vascular calcification.

4.4 Serum creatinine

The current consensus is that AVF is the most preferred vascular access in dialysis patients. However, the timing of fistula establishment remains unclear. Y Wang, et al. (22) opined that before AVF surgery, vascular ultrasound and other examinations should be performed and evaluated, respectively. At the same time, Stolic et al. did not find SCr as an independent risk factor for AVF dysfunction (23). Based on our findings, SCr is not an independent risk factor for AVF dysfunction. In other words, the renal function (serum creatinine) at the initiation of dialysis does not strongly impact on the primary patency rate. As such, clinicians should not only consider the level of SCr, but also other factors before initiation of MHD.

4.5 Vessel diameter

This study also investigated the effect of vascular (arterial and venous) diameters on AVF primary dysfunction. Even though Misskey Jonathan and hamidzadeh Ramin (24) found radial arterial diameter (<2.1mm) to be an independent risk factors for AVF dysfunction. However, we report dissimilar findings: Vascular diameter not to be an risk factor for AVF dysfunction, probably due to strong emphasis on vascular diameter before surgery in our center.